Normocytic Anemia (ACD, Renal, Mixed)

📋 Key Information Summary

📋

Normocytic anaemia (MCV 80–100 fL) encompasses anaemia of chronic disease (ACD), renal anaemia, and mixed-pattern anaemia — always consider overlap with iron deficiency.
ACD is the most common cause of normocytic anaemia worldwide, driven by hepcidin-mediated iron sequestration in the setting of chronic inflammation, infection, or malignancy.
Renal anaemia results primarily from inadequate erythropoietin (EPO) production and shortened red cell survival in chronic kidney disease (CKD stages 3–5).
A mixed pattern (ACD + iron deficiency) is common in CKD patients on dialysis, post-surgical patients, and those with chronic GI blood loss — ferritin may be deceptively normal or elevated.
Initial evaluation must include a thorough history of chronic diseases, medications, alcohol use, nutritional status, and a targeted examination for signs of chronic illness, malignancy, and haemolysis.
Core investigations: FBC with reticulocyte count, iron studies (ferritin, serum iron, transferrin saturation [TSAT]), creatinine/eGFR, LFTs, TSH, and inflammatory markers (CRP, ESR).
ACD iron pattern: low serum iron, low/normal TIBC, normal or elevated ferritin, low TSAT — contrast with iron deficiency: low iron, high TIBC, low ferritin.
Renal anaemia is suggested when eGFR <30 mL/min/1.73 m² with a normocytic, hypoproliferative picture (low reticulocyte count, no evidence of blood loss or haemolysis).
Serum EPO levels are NOT routinely required — the diagnosis of renal anaemia is clinical, based on CKD stage and exclusion of other causes.
ESAs (erythropoiesis-stimulating agents) such as darbepoetin alfa and epoetin alfa are PBS-listed for CKD-related anaemia (Authority Required) — target Hb 100–115 g/L.
IV iron (ferric carboxymaltose, iron polymaltose) is preferred in CKD and ACD when oral iron fails or is poorly tolerated — check PBS authority criteria.
Urgent haematology referral is indicated for suspected bone marrow failure, haemolysis, unexplained normocytic anaemia, abnormal blood film (blasts, dysplasia), or transfusion-dependent cases.
Aboriginal and Torres Strait Islander Australians have higher rates of CKD and chronic infection — maintain a low threshold for screening and culturally safe management.

Introduction & Australian Epidemiology

Normocytic anaemia — defined as haemoglobin below the reference range with a mean corpuscular volume (MCV) of 80–100 fL — is one of the most frequently encountered haematological findings in Australian primary care. It represents a heterogeneous group of disorders, the most common of which are anaemia of chronic disease (ACD), renal anaemia, and mixed-pattern anaemia where iron deficiency coexists with a chronic inflammatory or renal process.

The World Health Organization defines anaemia as haemoglobin <130 g/L in men and <120 g/L in non-pregnant women. In Australia, the 2011–2012 Australian Health Survey estimated that approximately 6% of men and 12% of women have haemoglobin below these thresholds, with prevalence rising sharply in older adults and those with comorbid chronic disease.

⚠️

Prevalence in CKD: Up to 40–60% of Australians with CKD stages 3b–5 have anaemia, and this rises to >80% in those on dialysis. Early identification and management reduce cardiovascular morbidity and improve quality of life.

ACD (also termed anaemia of inflammation) is the second most common anaemia globally after iron deficiency. In Australian hospital settings, it is frequently observed in patients with rheumatoid arthritis, chronic infections (including chronic hepatitis B/C, tuberculosis, and HIV), inflammatory bowel disease, heart failure, and malignancy. Renal anaemia is the dominant cause of normocytic anaemia in CKD populations, driven by inadequate erythropoietin production and disordered iron homeostasis.

Mixed-pattern anaemia is particularly important to recognise because the coexistence of ACD and iron deficiency alters the expected laboratory pattern, often masking true iron deficiency behind a normal or elevated ferritin. This leads to under-treatment and worse outcomes if not identified and managed appropriately.

Aetiology	Mechanism	Key Context
Anaemia of chronic disease (ACD)	Hepcidin-mediated iron sequestration; reduced EPO response; shortened RBC survival	Chronic infection, autoimmune disease, malignancy, heart failure
Renal anaemia	Reduced EPO production; uraemic toxin inhibition of erythropoiesis; shortened RBC lifespan	CKD stages 3–5, dialysis patients, renal transplant recipients
Mixed (ACD + iron deficiency)	Overlapping iron sequestration with true iron depletion (GI loss, dietary, post-surgical)	CKD with GI blood loss, post-surgical patients, chronic disease with menorrhagia

Initial Evaluation — History & Examination

A systematic initial evaluation is essential to narrow the differential diagnosis and identify the underlying cause of normocytic anaemia. The approach should integrate a thorough history with a targeted physical examination.

History

Elicit the following key historical domains:

Chronic diseases: Document known CKD (and stage), rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, chronic liver disease, heart failure, diabetes mellitus, chronic infections (HIV, hepatitis B/C, tuberculosis), and malignancy (type, stage, treatment).
Medications: ACE inhibitors, ARBs (may suppress EPO production), NSAIDs, corticosteroids, chemotherapy agents, anticoagulants, proton pump inhibitors (reduce iron absorption), metformin (associated with B12 deficiency), and any erythropoiesis-stimulating agents.
Alcohol intake: Quantify using standard drinks per week; heavy alcohol use (>14 standard drinks/week) contributes to myelosuppression, liver disease, and nutritional deficiency.
Nutritional history: Dietary iron intake, vegetarian/vegan diet, malabsorption syndromes, bariatric surgery history, recent weight loss.
Symptoms of anaemia: Fatigue, exertional dyspnoea, reduced exercise tolerance, palpitations, angina, cognitive impairment — quantify functional limitation.
Bleeding history: Menorrhagia, GI blood loss (haematochezia, melaena, positive FOBT), haematuria, recurrent epistaxis — even in the setting of ACD, concurrent blood loss creates a mixed picture.
Family and ethnic history: Haemoglobinopathies (relevant in Mediterranean, South-East Asian, and African ancestry), hereditary haemochromatosis (Celtic/Northern European ancestry).

Physical Examination

Focus on signs of chronic illness, specific organ involvement, and features suggesting alternative or additional diagnoses:

1

General

Pallor (conjunctival, palmar), cachexia, weight loss, lymphadenopathy (supraclavicular, axillary, inguinal), jaundice (haemolysis or liver disease).

2

Cardiovascular

Tachycardia, flow murmurs, signs of heart failure (raised JVP, peripheral oedema, bibasal crackles) — both a cause and consequence of chronic anaemia.

3

Musculoskeletal & Skin

Joint swelling/synovitis (rheumatoid arthritis, SLE), skin rashes, psoriatic plaques, vasculitic lesions, Raynaud's phenomenon.

4

Abdominal

Hepatomegaly, splenomegaly, ascites, masses — evaluate for liver disease, malignancy, or portal hypertension contributing to anaemia.

5

Stigmata of CKD

A-V fistula (dialysis access), peripherally inserted central catheter, pallor with yellowish skin (uraemic pallor), peripheral neuropathy.

🚨

Red flags requiring urgent assessment: Significant weight loss, night sweats, lymphadenopathy, hepatosplenomegaly, bone pain, abnormal bruising — consider haematological malignancy and refer urgently to haematology.

Core Investigations

The initial laboratory workup for normocytic anaemia should be comprehensive yet targeted, aiming to confirm the anaemia pattern, identify the underlying aetiology, and detect coexisting deficiencies.

Essential Full Blood Count (FBC) with Red Cell Indices Confirms normocytic pattern (MCV 80–100 fL). Assess Hb, MCV, MCH, MCHC, RDW (elevated in mixed deficiency), white cell count, and platelet count. MBS Item 65070.

Essential Reticulocyte Count (Absolute) Hypoproliferative picture (low reticulocytes) in ACD and renal anaemia; appropriate or elevated reticulocytes suggest haemolysis or acute blood loss. Reticulocyte production index (RPI) <2 indicates inadequate marrow response. MBS Item 65097.

Essential Iron Studies Serum iron, serum ferritin, transferrin, TIBC, transferrin saturation (TSAT). Critical for distinguishing ACD from iron deficiency from mixed patterns. MBS Items 66570, 66571, 66573.

Essential Creatinine & eGFR CKD-EPI equation preferred. eGFR <60 mL/min/1.73 m² suggests CKD; <30 strongly associated with renal anaemia. MBS Item 66500.

Essential Inflammatory Markers — CRP & ESR CRP >5 mg/L or ESR elevation supports ACD/inflammatory aetiology. CRP is more specific; ESR may be influenced by anaemia itself. MBS Item 65074 (CRP).

Available Liver Function Tests (LFTs) ALT, AST, GGT, ALP, bilirubin, albumin. Chronic liver disease causes ACD; GGT and MCV help identify alcohol excess. Hypoalbuminaemia indicates chronic inflammation or malnutrition. MBS Item 66515.

Available Thyroid Function — TSH Hypothyroidism causes normocytic anaemia and must be excluded. TSH alone is sufficient in most cases; add free T4 if TSH abnormal. MBS Item 66710.

Available Blood Film (Peripheral Smear) Evaluate for rouleaux formation (chronic inflammation), schistocytes (microangiopathy), target cells (liver disease), Howell-Jolly bodies (hyposplenism), blasts or dysplastic cells (malignancy/MDS). MBS Item 65085.

Available Vitamin B12 & Folate Rule out coexisting deficiency, particularly in CKD, malnutrition, elderly, or patients on metformin/pantoprazole. May mask concurrent macrocytosis. MBS Items 66549, 66548.

Specialist Soluble Transferrin Receptor (sTfR) & sTfR/log Ferritin Index Helps distinguish ACD from iron deficiency when ferritin is misleadingly normal. Elevated sTfR suggests true iron deficiency even in the setting of inflammation. MBS Item 66573. Request through haematology consultation.

Specialist Bone Marrow Aspirate & Trephine Biopsy Reserved for unexplained anaemia, suspected MDS, myelofibrosis, marrow infiltration, or when non-invasive tests are inconclusive. Requires haematology referral.

💡

Interpreting ferritin in inflammation: Ferritin is an acute-phase reactant. In ACD, ferritin may be normal or elevated despite depleted iron stores. A ferritin <30 µg/L reliably indicates iron deficiency even in the presence of inflammation; a ferritin of 30–100 µg/L with elevated CRP and TSAT <20% is suggestive of mixed ACD/iron deficiency.

Distinguishing ACD, Renal, & Mixed Anaemia

The iron study pattern is the single most useful discriminator between ACD, renal anaemia, and mixed aetiology. Combined with clinical context (eGFR, inflammatory markers, blood loss history), these patterns enable confident classification.

Parameter	ACD (Pure)	Iron Deficiency (Pure)	Renal Anaemia	Mixed (ACD + IDA)
MCV	Normal (80–100 fL)	Low (often <80 fL)	Normal (80–100 fL)	Normal to low
Serum iron	↓	↓	↓ or normal	↓
TIBC	↓ or normal	↑	Normal or ↓	Normal or ↓
Ferritin	Normal or ↑	↓ (<30 µg/L)	Normal or ↑	Normal or ↑ (misleading)
TSAT	↓ (<20%)	↓ (<16%)	↓ or low-normal	↓ (<20%)
CRP/ESR	↑	Normal	May be ↑ (uraemia)	↑
eGFR	Variable	Normal	↓ (<30 mL/min)	↓ (CKD present)
Reticulocytes	↓	↓	↓ (inappropriately)	↓
sTfR	Normal	↑	Normal	↑
sTfR/log Ferritin	<1	>2	<1	>1 (equivocal)

Anaemia of Chronic Disease (ACD)

ACD is driven by the hepcidin–ferroportin axis. Inflammatory cytokines (especially IL-6) upregulate hepcidin synthesis in the liver. Hepcidin binds ferroportin on enterocytes and macrophages, causing its internalisation and degradation. This blocks both dietary iron absorption and macrophage iron release, resulting in functional iron deficiency — iron is present in the body but sequestered and unavailable for erythropoiesis.

Additional mechanisms in ACD include:

Blunted EPO production relative to the degree of anaemia
Direct suppression of erythroid progenitors by inflammatory cytokines (TNF-α, IFN-γ, IL-1β)
Shortened red blood cell survival due to reticuloendothelial activation

Renal Anaemia

Renal anaemia is primarily driven by reduced erythropoietin (EPO) production by peritubular fibroblasts in the damaged kidney. Additional contributing factors include uraemic toxin inhibition of erythropoiesis, shortened RBC lifespan in the uraemic milieu, and iron deficiency (from chronic blood loss in dialysis circuits, frequent phlebotomy, and reduced GI absorption). In patients with CKD stages 3b–5, renal anaemia should be diagnosed when:

Hb is below the target range (typically <100 g/L, though treatment initiation thresholds vary)
There is a normocytic, hypoproliferative picture
Other causes (iron deficiency, B12/folate deficiency, haemolysis, blood loss) have been excluded

Mixed Pattern (ACD + Iron Deficiency)

The mixed pattern is the most challenging to diagnose because ACD raises ferritin and lowers TIBC, masking the hallmarks of iron deficiency. Suspect mixed aetiology when:

⚠️

Indicators of mixed ACD + iron deficiency:

Ferritin 30–100 µg/L with elevated CRP and TSAT <20%
Microcytosis developing in a previously normocytic patient with known ACD
RDW elevated (>15%) — suggests anisocytosis from dual populations
Clinical context: CKD with GI blood loss, post-operative patients, heavy menses with concurrent inflammatory disease
Elevated sTfR (>1.76 mg/L) with normal or elevated ferritin

In CKD patients on haemodialysis, the combination of chronic inflammation, EPO deficiency, and dialysis-related blood loss makes the mixed pattern extremely common. Kidney Health Australia KHA-CARI guidelines recommend iron studies every 1–3 months in this population, with a target TSAT >20% and ferritin >100 µg/L (but <500 µg/L to avoid iron overload).

Additional Investigations & MBS Considerations

Beyond the core panel, additional investigations may be warranted based on clinical context and initial results:

Investigation	Indication	MBS Item	Interpretation Notes
Haemoglobin electrophoresis / HPLC	If thalassaemia trait suspected (persistent low MCV, microcytosis disproportionate to iron levels)	66576	HbA2 >3.5% suggests β-thalassaemia trait; request through pathology lab with haematology approval
Direct antiglobulin test (DAT / Coombs)	Suspected autoimmune haemolytic anaemia (elevated reticulocytes, jaundice, elevated LDH, low haptoglobin)	65125	Positive DAT supports immune-mediated haemolysis; requires haematology referral
LDH, haptoglobin, bilirubin	Haemolysis screen — elevated LDH and unconjugated bilirubin with low haptoglobin	66515 (LFT panel); haptoglobin 66577	If haemolysis confirmed → urgent haematology referral
Faecal occult blood test (FOBT)	Unexplained iron deficiency component, age-appropriate bowel cancer screening	66584	Positive → colonoscopy referral (National Bowel Cancer Screening Programme or private)
Hepatitis B/C serology, HIV	Chronic infections as a cause of ACD, risk-factor guided	69304, 69316	Treat underlying infection to resolve ACD
Autoimmune screen (ANA, RF, anti-CCP)	Suspected autoimmune disease (joint symptoms, rash, positive inflammatory markers)	69300 (ANA); 66559 (RF)	Positive → rheumatology referral
Serum EPO level	Rarely required; consider when CKD is borderline and diagnosis uncertain	Not routinely MBS-listed — private cost	Inappropriately low EPO for degree of anaemia supports renal aetiology

💡

Fibroblast growth factor 23 (FGF-23): Emerging biomarker in CKD mineral-bone disease but NOT yet routine for anaemia assessment. Not MBS-listed.

Risk Stratification & Severity Assessment

Severity assessment guides urgency of investigation, need for transfusion, and therapeutic intensity:

Mild

Hb 100–119 g/L (F) / 100–129 g/L (M)

Often asymptomatic or minimal exertional fatigue. Functional capacity preserved. Usually discovered incidentally on routine bloods.

Setting: Outpatient GP management — investigate, treat underlying cause, monitor

Moderate

Hb 80–99 g/L

Exertional dyspnoea, fatigue, reduced exercise tolerance, tachycardia. May impact activities of daily living. Cardiovascular risk increases in elderly and those with cardiac disease.

Setting: Outpatient with close follow-up — investigate urgently, consider transfusion if symptomatic or cardiac disease, initiate ESAs if CKD

Severe

Hb <80 g/L

Resting dyspnoea, angina, haemodynamic compromise (tachycardia, hypotension), cognitive impairment, syncope. High risk of cardiac decompensation especially in elderly or pre-existing cardiac disease.

Setting: Hospital assessment — consider packed red cell transfusion (single unit, reassess), urgent investigation for cause

🚨

Transfusion threshold: In stable, non-bleeding patients, a restrictive transfusion threshold of Hb <70 g/L is supported by Australian Red Cross Lifeblood guidelines and NICE NG24. For patients with acute coronary syndrome or active cardiac disease, target Hb 80–100 g/L. Always transfuse with a single-unit policy and reassess Hb before issuing the next unit.

Management & Directed Therapy

Principles of Management

Treatment of normocytic anaemia is directed at the underlying cause. There is no role for empiric iron supplementation in pure ACD (iron is sequestered, not deficient), and transfusion is reserved for haemodynamic compromise or severe symptomatic anaemia.

1

Treat the underlying disease

ACD resolves when the inflammatory stimulus is controlled. Optimise RA treatment (DMARDs, biologics), treat chronic infections, manage malignancy, and control heart failure.

2

Correct coexisting deficiencies

Iron deficiency (oral or IV), B12 deficiency (IM hydroxocobalamin), folate deficiency — correct before attributing anaemia to ACD or CKD alone.

3

ESAs for renal anaemia

Initiate ESAs when Hb <100 g/L in CKD after iron repletion. Target Hb 100–115 g/L. Avoid exceeding 120 g/L (increased cardiovascular risk — TREAT trial).

4

IV iron when oral fails

In CKD/ACD, IV iron (ferric carboxymaltose, iron polymaltose) is preferred due to GI intolerance and poor oral absorption. Check TSAT and ferritin prior to infusion.

Pharmacotherapy — Drug Cards

💊

Darbepoetin Alfa

Aranesp® · Amgen · Long-acting erythropoiesis-stimulating agent

Adult dose CKD (non-dialysis): 0.45 µg/kg SC once weekly, or 100 µg SC once every 2 weeks. Haemodialysis: 0.45 µg/kg SC/IV once weekly or 60 µg once weekly. Titrate every 4 weeks to maintain Hb 100–115 g/L.

Paediatric dose ≥1 year: 0.45 µg/kg SC once weekly (limited data in <1 year). Titrate to age-appropriate Hb target.

Renal adjustment Dose is per kg; no specific adjustment — used in the context of CKD.

Hepatic adjustment No dose adjustment required.

Key monitoring Hb every 2–4 weeks during titration, then monthly. Monitor BP — hypertension is a class effect. Iron studies must be adequate before initiation (TSAT >20%, ferritin >100 µg/L).

PBS status Authority Required — CKD-related anaemia

💊

Epoetin Alfa

Eprex® · Janssen-Cilag · Erythropoiesis-stimulating agent

Adult dose Haemodialysis: 50 IU/kg IV three times weekly (at end of dialysis session). Non-dialysis CKD: 50 IU/kg SC three times weekly. Titrate every 4 weeks by 25 IU/kg increments.

Paediatric dose 50 IU/kg SC/IV three times weekly, titrate to response. Neonates: limited data, specialist supervision required.

Renal adjustment Indicated for CKD — no specific adjustment beyond monitoring.

Key monitoring Hb every 2–4 weeks initially. Monitor BP. Withhold if Hb >120 g/L or rapid rise (>10 g/L in 2 weeks). Pure red cell aplasia (PRCA) — very rare, report to TGA if suspected.

PBS status Authority Required — CKD-related anaemia

💊

Ferric Carboxymaltose

Ferinject® · Vifor Pharma · IV iron replacement

Adult dose Total iron deficit calculated by Ganzoni formula or simplified: Hb <100 g/L → 1000 mg IV infusion over 15 minutes (max 20 mg/kg for body weight <66 kg). May repeat if needed after 1 week.

Paediatric dose ≥14 years: 15 mg/kg (max 750 mg) IV in a single session. Not recommended <14 years.

Renal adjustment No dose adjustment — can be safely used in CKD and dialysis patients. Do NOT mix with dialysate.

Hepatic adjustment Use with caution if ALT >3× ULN. Avoid in active hepatitis exacerbation.

Key monitoring Check Hb at 4 weeks post-infusion. Iron studies at 4–8 weeks. Monitor for hypophosphataemia (risk with ferric carboxymaltose — FGF23 mediated). Infusion reactions are rare (<1%).

PBS status Authority Required — when oral iron fails/intolerant, CKD, IBD

💊

Iron Polymaltose (Iron(III) Hydroxide Polymaltose Complex)

Ferro® / Ferrum H® · Various · IV/IM iron replacement

Adult dose IV: Total dose infusion (TDI) calculated by Ganzoni formula, diluted in 250 mL NaCl 0.9%, infused over 4–6 hours. Test dose 25 mg IV required first. IM: 100 mg deep gluteal injection, alternate sides.

Paediatric dose IV (TDI): calculated by weight, max 20 mg/kg. Test dose 1 mg/kg required. Specialist supervision recommended.

Renal adjustment No specific adjustment — frequently used in CKD/dialysis.

Key monitoring Observe for 30 min post-test dose (anaphylaxis risk). Hb at 4 weeks. Iron studies at 4–8 weeks.

PBS status PBS General Benefit (IV/IM)

💊

Ferrous Sulfate (Oral Iron)

Ferro-Gradumet® · Various · Oral iron replacement

Adult dose 325 mg (105 mg elemental iron) PO once daily (alternate day dosing shown to improve absorption). Continue for 3 months after Hb normalisation to replenish stores.

Paediatric dose 3–6 mg/kg/day elemental iron in divided doses (liquid formulation for young children).

Renal adjustment No specific adjustment. Oral iron often poorly absorbed and tolerated in CKD — consider IV early.

Key notes Take on empty stomach or with vitamin C (200 mg) to enhance absorption. Avoid concurrent tea, coffee, calcium, and antacids. Common side effects: constipation, nausea, dark stools. If intolerance → switch to alternate-day dosing or IV iron.

PBS status PBS General Benefit

HIF-PHI Agents — Roxadustat

Roxadustat (Evrenzo®) is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stimulates endogenous EPO production and improves iron availability. It is TGA-registered in Australia for CKD-related anaemia in adult patients on dialysis and not on dialysis. It is taken orally, which is an advantage over injectable ESAs. However, it is NOT currently PBS-listed and remains Authority Required (private script or hospital supply). Prescribing requires haematology or nephrology oversight. Key safety signals include increased cardiovascular events (ASCEND programme), thrombosis risk, and potential for tumour growth in undiagnosed malignancy.

⚠️

Do NOT use ESAs in: Uncontrolled hypertension, pure red cell aplasia (prior ESA-induced PRCA), active malignancy without oncology guidance, or anaemia not due to CKD/EPO deficiency. ESAs increase thrombotic and cardiovascular risk — always replete iron first and use the lowest effective dose.

Transfusion

Packed red blood cell (PRBC) transfusion is a supportive measure, not a treatment for the underlying cause. In Australia, transfusion is guided by the Australian Red Cross Lifeblood clinical guidelines and the National Blood Authority (NBA) Patient Blood Management (PBM) Guidelines. Key principles:

Restrictive strategy: Hb <70 g/L trigger for stable, non-bleeding patients
Liberal strategy: Hb <80 g/L trigger for acute coronary syndrome, post-cardiac surgery, or active cardiac disease
Single-unit transfusion policy — transfuse one unit, reassess Hb and symptoms before issuing a second
Each unit PRBC raises Hb by approximately 10 g/L (in a 70 kg adult)
Ensure ABO/Rh grouping, antibody screen, and crossmatch completed
Monitor for transfusion reactions: fever, rigors, urticaria, dyspnoea, hypotension (acute haemolytic reaction is a medical emergency)

Monitoring

Monitoring frequency depends on the underlying aetiology, severity, and treatment modality:

Scenario	Monitoring	Frequency	Targets
ACD (stable, managed)	FBC, CRP, iron studies	Every 3–6 months	Hb stable, underlying disease controlled, CRP trending down
CKD not on dialysis — initiating ESA	FBC every 2–4 weeks (titration phase); iron studies monthly	Every 2–4 weeks initially, then monthly once stable	Hb 100–115 g/L; TSAT >20%; ferritin 100–500 µg/L
Haemodialysis — stable on ESA	FBC monthly; iron studies every 1–3 months	Monthly	Hb 100–115 g/L; TSAT 20–50%; ferritin 200–500 µg/L
Post IV iron infusion	Hb at 4 weeks; iron studies at 4–8 weeks	4–8 weeks post-infusion	Hb rise ≥10 g/L or to target; TSAT >20%; ferritin >100 µg/L
Post transfusion	Hb 15–60 min post-unit; monitor for reaction	Per unit	Hb increment ~10 g/L per unit; clinical improvement

💡

ESA dose adjustment: If Hb rises >10 g/L in a 2-week period or exceeds 120 g/L, reduce ESA dose by 25–50%. Persistent supraphysiological Hb levels increase cardiovascular risk (TREAT trial: target Hb 130 g/L in diabetic CKD patients was associated with increased stroke).

When to Refer

Timely referral to haematology or other specialists is critical when the aetiology is unclear, the anaemia is severe, or features suggest a sinister underlying cause. The following indications warrant specialist involvement:

1

Haematology referral — Urgent

Abnormal blood film: blasts, dysplastic cells, leucoerythroblastic film (nucleated RBCs + myeloid precursors)
Suspected haemolysis: elevated reticulocytes, jaundice, elevated LDH, low haptoglobin, positive DAT
Pancytopenia or bicytopenia
Unexplained normocytic anaemia not responding to standard management after 4–8 weeks
Pure red cell aplasia (very low reticulocytes, isolated anaemia)
Suspected myelodysplastic syndrome (MDS) — especially in patients >60 years with macrocytosis, neutropenia, or thrombocytopenia

2

Haematology referral — Routine

Transfusion-dependent patients for PBM optimisation
Patients requiring IV iron when local infusion services are unavailable
Complicated CKD anaemia management (ESA resistance, recurrent iron deficiency)
Diagnostic uncertainty after initial workup

3

Other specialist referrals

Nephrology: CKD stages 3b–5 requiring ESA initiation or complex iron management
Gastroenterology: Suspected GI blood loss (FOBT positive, iron deficiency component), suspected coeliac disease or IBD
Rheumatology: Undiagnosed autoimmune disease with ACD
Cardiology: Anaemia with heart failure or ischaemic heart disease — cardiorenal-anaemia syndrome
Endocrinology: Unexplained anaemia with endocrine features (adrenal insufficiency, hypothyroidism)

🚨

Leucoerythroblastic film: The presence of nucleated red cells and immature myeloid cells in the peripheral blood suggests bone marrow infiltration (metastatic malignancy, myelofibrosis, granulomatous disease) or severe stress haematopoiesis. This requires urgent haematology review and bone marrow biopsy.

Special Populations

🤰 Pregnancy

Iron requirements: Increase significantly in 2nd/3rd trimester (approximately 1000 mg additional iron across pregnancy). Assess iron studies at booking, 28 weeks, and postnatally.

Oral iron: First-line: ferrous sulfate 325 mg PO daily or alternate days. If intolerant or malabsorption, consider IV iron (ferric carboxymaltose is considered safe in 2nd/3rd trimester per RANZCOG).

ESAs: Contraindicated in pregnancy — Category B3. No role in pregnancy-related anaemia.

Physiological haemodilution: Hb may fall to 100–110 g/L due to plasma volume expansion — this is physiological and does not require treatment if asymptomatic.

ACD in pregnancy: uncommon in isolation but may coexist with autoimmune conditions. Multidisciplinary management with obstetrics and haematology recommended.

👶 Paediatrics

Definition: Age-specific Hb thresholds — WHO: 6 months–5 years <110 g/L; 5–12 years <115 g/L; 12–15 years <120 g/L.

Common causes: Iron deficiency is the most common cause of paediatric anaemia in Australia, but ACD occurs in chronic infections, juvenile idiopathic arthritis (JIA), IBD, and CKD (congenital renal disease).

Renal anaemia in children: Congenital anomalies of the kidney and urinary tract (CAKUT), reflux nephropathy. Darbepoetin and epoetin are TGA-approved for use in children ≥1 year.

Oral iron dosing: Ferrous sulfate liquid: 3–6 mg/kg/day elemental iron in 1–2 divided doses. Alternate-day dosing may improve compliance.

Paediatric IV iron (ferric carboxymaltose): approved ≥14 years. For younger children, iron polymaltose IV under specialist supervision is preferred. Always exclude coeliac disease (anti-tTG IgA) in iron-deficient children.

🧓 Elderly (≥65 years)

Prevalence: Anaemia affects 10–20% of community-dwelling Australians aged ≥65 years and up to 50% of aged care residents. Multifactorial aetiology is the norm.

Common contributors: CKD (high prevalence of stages 3–5), chronic inflammation (osteoarthritis, diabetes, COPD), myelodysplasia (incidence rises with age), GI malignancy, medications (NSAIDs, PPIs, ACEi).

ESA caution: Higher cardiovascular risk in elderly — TREAT trial data apply. Avoid targeting Hb >120 g/L. Blood pressure monitoring is essential.

Transfusion threshold: Restrictive (Hb <70 g/L) unless active cardiac disease. Consider frailty, falls risk, and quality of life in decision-making.

Always investigate new-onset normocytic anaemia in the elderly for occult malignancy — particularly if MDS or marrow failure is considered. FOBT and age-appropriate cancer screening should be completed.

🫘 Renal Impairment

CKD stages 1–2: Anaemia uncommon — investigate other causes first.

CKD stage 3a (eGFR 45–59): Anaemia screening recommended. Treat iron deficiency first; ESAs rarely needed at this stage.

CKD stage 3b–4 (eGFR 15–44): Renal anaemia becomes likely. Replete iron (TSAT >20%, ferritin >100 µg/L), then initiate ESA if Hb remains <100 g/L. Nephrology co-management recommended.

CKD stage 5 / Dialysis: Almost universal anaemia. ESA + IV iron as standard. Target Hb 100–115 g/L. Monitor iron every 1–3 months. ESA resistance: consider causes (infection, hyperparathyroidism, aluminium toxicity, PRCA).

Renal transplant: Anaemia may resolve post-transplant, but ESA use is complicated by immunosuppression and graft function. Haemoglobin targets and management per nephrologist.

All IV iron formulations are safe in CKD. Ferric carboxymaltose allows rapid repletion (1000 mg over 15 minutes) without a test dose — preferred in CKD outpatients.

🫁 Hepatic Impairment

Chronic liver disease: Causes ACD via inflammation, portal hypertensive splenomegaly (sequestration), impaired EPO production, and GI variceal blood loss. MCV may be elevated due to liver disease (target cells) or alcohol.

Iron studies interpretation: Ferritin is an acute-phase reactant AND is elevated in hepatic iron overload. In chronic liver disease, ferritin >200 µg/L (F) or >300 µg/L (M) does not reliably exclude iron deficiency — use TSAT and sTfR.

Treatment: Treat the underlying liver disease. IV iron is preferred if malabsorption or variceal bleeding. Avoid oral iron in active variceal bleeding (may cause nausea/vomiting).

In hereditary haemochromatosis, iron studies show elevated ferritin and TSAT >45% — venesection, not supplementation, is the treatment. Genetic testing (HFE C282Y/H63D) should be performed in unexplained iron overload.

🛡️ Immunocompromised

HIV: ACD is common (chronic immune activation, opportunistic infections). Antiretroviral therapy (ART) may cause bone marrow suppression (zidovudine). Iron supplementation should be cautious — unbound iron may worsen infection risk.

Transplant recipients: Post-transplant anaemia (PTA) affects up to 40% of solid organ transplant recipients. Causes include ESA resistance (due to immunosuppressants), infection, and graft dysfunction.

Biologics/DMARDs: Methotrexate causes folate deficiency and myelosuppression. TNF inhibitors may improve ACD by controlling inflammation. Rituximab can cause delayed-onset anaemia.

In immunocompromised patients, always exclude infection (including opportunistic) as a cause of ACD before attributing it to the underlying condition alone. Blood cultures and targeted infection screening may be warranted.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a disproportionate burden of chronic disease, including CKD, rheumatic heart disease, chronic infections (particularly rheumatic fever sequelae and hepatitis B), and diabetes — all causes of normocytic anaemia. Culturally safe, trauma-informed care is essential.

CKD prevalence

Aboriginal and Torres Strait Islander Australians are 3.5× more likely to have CKD than non-Indigenous Australians. ESKD incidence is up to 8× higher. Anaemia screening should be routine from CKD stage 3 in this population (Kidney Health Australia recommendations).

Chronic infections

Rheumatic heart disease, chronic hepatitis B (higher prevalence in NT and remote communities), chronic suppurative lung disease, and strongyloidiasis all contribute to ACD. Infection screening should be integrated into anaemia workup.

Remote and rural access

Access to haematology specialists, infusion services, and laboratory testing may be limited in remote communities. Telehealth haematology consultations, remote infusion nursing, and point-of-care testing (iSTAT haemoglobin) can improve equity. Royal Flying Doctor Service (RFDS) facilitates transfusion and specialist access in remote areas.

Iron deficiency overlap

Iron deficiency is more prevalent in Aboriginal and Torres Strait Islander children and women of reproductive age due to dietary factors, parasitic infections, and heavy menses. Mixed ACD/iron deficiency patterns are common and must not be missed.

Cultural safety

Engage Aboriginal Health Workers and Aboriginal Community Controlled Health Organisations (ACCHOs) in care delivery. Ensure health literacy-appropriate education about anaemia and CKD. Respect kinship obligations and cultural practices during blood collection and transfusion. Use the ABS standard questions to identify Aboriginal and Torres Strait Islander status respectfully.

PBS access

Remote area Aboriginal and Torres Strait Islander patients are eligible for Section 100 (S100) Highly Specialised Drugs Program for ESAs and IV iron through hospital or remote area nurse administration. Closing the Gap PBS co-payment ensures no out-of-pocket cost for PBS medicines for eligible patients holding a concession card.

AIHW data

According to the AIHW (2023), anaemia is recorded in approximately 20–30% of Aboriginal and Torres Strait Islander hospitalisations for chronic disease — a significantly higher rate than the non-Indigenous population. Systematic screening and early intervention are key to Closing the Gap targets.

Quick Reference — Diagnostic Approach

Normocytic anaemia + ↑ CRP/ESR

Check iron studies → low iron, normal/high ferritin → ACD

Treat underlying cause

Monitor with CRP and Hb every 3–6 months

Normocytic anaemia + eGFR <30

Iron replete (TSAT >20%, ferritin >100) → ESA if Hb <100

Ongoing — lifelong in CKD

Nephrology co-management from CKD 3b

Normocytic anaemia + ↑ CRP + low ferritin

Mixed ACD + IDA → IV iron + treat inflammation

Review at 4–8 weeks post-iron

sTfR helps confirm iron deficiency component

Unexplained normocytic anaemia

Blood film → if abnormal: haematology referral

Urgent if blasts/dysplasia

Consider marrow biopsy if cause unclear after 4–8 weeks

📚 References

1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023. doi:10.1056/NEJMra041809
2. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783–788. doi:10.1182/blood-2003-03-0672
3. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631–1634. doi:10.1681/ASN.2011111078
4. Kidney Health Australia. Chronic Kidney Disease (CKD) Management in Primary Care. 4th ed. Melbourne: Kidney Health Australia; 2020.
5. Locatelli F, Bárány P, Covic A, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279–335.
6. National Blood Authority (NBA). Patient Blood Management Guidelines: Module 2 — Perioperative. Canberra: NBA; 2012 (updated 2019).
7. Australian Institute of Health and Welfare (AIHW). Anaemia. AIHW; 2023. Available at: www.aihw.gov.au.
8. Pasricha SR, Flecknoe-Brown SC, Allen KJ, et al. Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust. 2010;193(9):525–532. doi:10.5694/j.1326-5377.2010.tb04151.x
9. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease (TREAT). N Engl J Med. 2009;361(21):2019–2032. doi:10.1056/NEJMoa0907845
10. Cullis JO. Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol. 2011;154(3):289–300. doi:10.1111/j.1365-2141.2011.08741.x
11. Royal Australian College of General Practitioners (RACGP). Clinical guideline for the diagnosis and management of iron deficiency in adults. RACGP; 2022.
12. Australian Red Cross Lifeblood. Clinical guidelines for blood transfusion. 3rd ed. Sydney: Australian Red Cross Lifeblood; 2023.
13. Ganz T, Aronoff GR, Gaillard CA, et al. Iron administration, infection, and anemia management in CKD: untangling the effects of intravenous iron therapy on immunity and infection risk. Kidney Med. 2020;2(5):601–613.
14. Australian Institute of Health and Welfare (AIHW). Chronic kidney disease in Aboriginal and Torres Strait Islander people. Cat. no. PHE 211. Canberra: AIHW; 2023.